NasdaqGS:MDGLBiotechs
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After New Rezdiffra Data And Analyst Upgrades
Madrigal Pharmaceuticals (MDGL) is back in focus after new Phase 3 and real world data presented at the EASL Congress 2026 linked its MASH drug Rezdiffra to improved liver and cardiovascular risk markers.
See our latest analysis for Madrigal Pharmaceuticals.
Despite a recent pullback, including a 7 day share price return of down 4.5% and some profit taking after insider sales, Madrigal’s 1 year total shareholder return of about 80% and 5 year total shareholder return of over 3.5x suggest...